Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Apellis Pharmaceuticals
Apellis Pharmaceuticals
(APLS)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Empaveli
Pegcetacoplan
2021-05-14
2026-2038
Paroxysmal hemoglobinuria
Syfovre
Pegcetacoplan
2023-02-17
2026-2038
Paroxysmal hemoglobinuria
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Pegcetacoplan
ischemic stroke
,
cerebral infarction
,
reperfusion injury
,
thromboinflammation
,
wet macular degeneration
,
amyotrophic lateral sclerosis
,
motor neuron disease
,
sclerosis
,
kidney diseases
,
iga glomerulonephritis
,
membranous glomerulonephritis
,
lupus nephritis
,
nephritis
,
anemia
,
hemolysis
,
hemolytic anemia
,
ovarian neoplasms
,
endometrioid carcinoma
,
serous cystadenocarcinoma
,
fallopian tube neoplasms
,
carcinosarcoma
,
acinar cell carcinoma
,
pancreatic ductal carcinoma
,
pancreatic neoplasms
,
geographic atrophy
,
macular degeneration
,
paroxysmal hemoglobinuria
,
hemoglobinuria
,
glomerulonephritis
,
membranoproliferative glomerulonephritis
,
atrophy
,
kidney transplantation
,
hemolytic anemia autoimmune
,
chronic kidney failure
,
delayed graft function
Aspartame
sepsis
Nepidermin
multiple sclerosis
,
neuritis
,
optic neuritis
,
sclerosis
Decellularized dermal allograft
leukemia
,
non-hodgkin lymphoma
,
precursor cell lymphoblastic leukemia-lymphoma
,
bcr-abl positive chronic myelogenous leukemia
,
myeloid leukemia
,
preleukemia
,
lymphoid leukemia
,
myelodysplastic syndromes
,
myeloid leukemia acute
,
induction chemotherapy
,
refractory anemia with excess of blasts
,
renal insufficiency
,
hematologic neoplasms
,
neoplasms
,
graft rejection
,
vascular diseases
,
kidney transplantation
,
psychology rejection
,
kidney diseases
,
lymphoma
,
b-cell chronic lymphocytic leukemia
,
hodgkin disease
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use